Want to see HOWL full AI Analyst Report?
HOWL Analyst Ratings
Currently, no data available
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
HOWL Stock 12 Month Forecast
There Are No Analyst Ratings for HOWL In The Last 3 Months.
| Highest Price Target― | Average Price Target― | Lowest Price Target― |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
HOWL Financial Forecast
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
$7
Buy
644.68%
Upside
Reiterated
02/17/26
H.C. Wainwright
$10→$4
Buy
325.53%
Upside
Reiterated
12/19/25
Wedbush
$3→$1
Hold
6.38%
Upside
Downgraded
12/19/25
Citizens JMP
―
Hold
―
Downgraded
12/19/25
Leerink Partners
$12→$10
Buy
963.83%
Upside
Reiterated
09/04/25
We believe 2H25 expansion cohorts could demonstrate meaningful WTX-124 monotherapy activity and added benefit in combination with pembrolizumab—especially in cutaneous melanoma, where we are particularly encouraged by management's reiteration that they see a path for monotherapy approval. However, the bar for excitement is high—20-30% confirmed overall response rates in 20-30 patients—given persistent investor skepticism toward IO mechanisms. Longer- term, we see potential for masked CD3 T-cell engagers (TCEs) to drive value for Werewolf. We are encouraged by recent progress applying the PREDATOR platform to TCEs, and view STEAP1 as an attractive lead target. We reiterate our Outperform and lower our price target (PT) to $10 (from $12) following updates for 2Q25 results and company guidance.
Jefferies
$11→$4
Buy
325.53%
Upside
Initiated
08/04/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
$7
Buy
644.68%
Upside
Reiterated
02/17/26
H.C. Wainwright
$10→$4
Buy
325.53%
Upside
Reiterated
12/19/25
Wedbush
$3→$1
Hold
6.38%
Upside
Downgraded
12/19/25
Citizens JMP
―
Hold
―
Downgraded
12/19/25
Leerink Partners
$12→$10
Buy
963.83%
Upside
Reiterated
09/04/25
We believe 2H25 expansion cohorts could demonstrate meaningful WTX-124 monotherapy activity and added benefit in combination with pembrolizumab—especially in cutaneous melanoma, where we are particularly encouraged by management's reiteration that they see a path for monotherapy approval. However, the bar for excitement is high—20-30% confirmed overall response rates in 20-30 patients—given persistent investor skepticism toward IO mechanisms. Longer- term, we see potential for masked CD3 T-cell engagers (TCEs) to drive value for Werewolf. We are encouraged by recent progress applying the PREDATOR platform to TCEs, and view STEAP1 as an attractive lead target. We reiterate our Outperform and lower our price target (PT) to $10 (from $12) following updates for 2Q25 results and company guidance.
Jefferies
$11→$4
Buy
325.53%
Upside
Initiated
08/04/25
Best Analysts Covering Werewolf Therapeutics
3 Months
Success Rate
8/17 ratings generated profit
Average Return
-4.59%
Copying Daina Graybosch's trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of -4.59% per trade.
1 Year
Success Rate
4/21 ratings generated profit
Average Return
-22.55%
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 19.05% of your transactions generating a profit, with an average return of -22.55% per trade.
2 Years
Success Rate
2/17 ratings generated profit
Average Return
-54.11%
Copying Daina Graybosch's trades and holding each position for 2 Years would result in 11.76% of your transactions generating a profit, with an average return of -54.11% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
HOWL Analyst Recommendation Trends
Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
1
1
0
0
0
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
1
0
0
0
Each month's total comprises the sum of three months' worth of ratings.
HOWL Stock Forecast FAQ
What is HOWL’s average 12-month price target, according to analysts?
Currently, no data Available
What is HOWL’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for HOWL, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is HOWL a Buy, Sell or Hold?
Currently, no data Available
What is Werewolf Therapeutics’s price target?
Currently, no data Available
What do analysts say about Werewolf Therapeutics?
Not enough analysts have published a price target to provide an average price target.
How can I buy shares of HOWL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.